Charles Schwab Investment Management Inc. Has $3.61 Million Position in InMode Ltd. (NASDAQ:INMD)

Charles Schwab Investment Management Inc. trimmed its position in shares of InMode Ltd. (NASDAQ:INMD) by 3.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,109 shares of the healthcare company’s stock after selling 8,472 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.25% of InMode worth $3,612,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in INMD. Carmel Capital Partners LLC raised its holdings in InMode by 6.9% in the 3rd quarter. Carmel Capital Partners LLC now owns 11,511 shares of the healthcare company’s stock valued at $195,000 after buying an additional 741 shares during the last quarter. Meritage Portfolio Management raised its stake in shares of InMode by 9.5% during the third quarter. Meritage Portfolio Management now owns 14,765 shares of the healthcare company’s stock valued at $250,000 after acquiring an additional 1,284 shares during the last quarter. Inspire Advisors LLC lifted its holdings in shares of InMode by 9.0% during the second quarter. Inspire Advisors LLC now owns 21,433 shares of the healthcare company’s stock worth $391,000 after purchasing an additional 1,778 shares during the period. Asset Dedication LLC bought a new stake in shares of InMode in the second quarter worth $33,000. Finally, North Growth Management Ltd. grew its stake in shares of InMode by 0.3% in the third quarter. North Growth Management Ltd. now owns 595,000 shares of the healthcare company’s stock worth $10,083,000 after purchasing an additional 2,000 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have commented on INMD shares. BTIG Research started coverage on InMode in a report on Thursday, October 17th. They set a “buy” rating and a $25.00 target price on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Thursday, October 31st. Finally, Barclays reduced their target price on InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a report on Monday, October 14th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, InMode has an average rating of “Hold” and an average price target of $22.60.

InMode Price Performance

Shares of NASDAQ:INMD opened at $18.26 on Friday. InMode Ltd. has a 1 year low of $14.87 and a 1 year high of $26.80. The business’s 50-day moving average is $18.08 and its 200-day moving average is $17.50. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of 9.87 and a beta of 2.07.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.